Ibex Medical Analytics, a leader in artificial intelligence (AI) for cancer diagnostics, has reached several key milestones in its mission to advance pathology. The company has reported an impressive 178% increase in new customers and a 157% surge in patient cases processed monthly using its AI solutions. This growth highlights the expanding adoption and trust in Ibex Medical Analytics’ cutting-edge technology worldwide.
In a significant endorsement of its capabilities, Ibex Medical Analytics’ Prostate AI solution was prominently featured in a recent study conducted with Quest Diagnostics. The study demonstrated that integrating Ibex Medical Analytics’ AI with Proscia‘s Concentriq® enterprise pathology platform significantly enhanced pathologists’ productivity, enabling them to process more cases per hour. The study, which included 180 randomized prostate cases, revealed that 100% of the participating pathologists expressed a strong preference for adopting AI-driven workflows following the study.
Additionally, Ibex Medical Analytics has achieved a major regulatory milestone by securing In Vitro Diagnostic Regulation (IVDR) certification for its prostate, breast, and gastric cancer diagnostic solutions. This certification from the European Union underscores the high standards of quality, safety, and performance that Ibex Medical Analytics upholds.
The company also announced the appointment of Ann Costello to its Board of Directors in April 2024. With her extensive background in diagnostics from Roche Diagnostics Solutions, Costello is expected to provide invaluable expertise in steering Ibex Medical Analytics through its next phase of strategic growth.
Joseph Mossel, CEO of Ibex Medical Analytics, commented on the recent developments: “Securing IVDR certification for our prostate, breast, and gastric AI solutions marks a pivotal achievement for Ibex Medical Analytics, highlighting our dedication to quality and innovation. As we advance through the latter part of the year and into 2025, these milestones reinforce our position in the market and reflect our commitment to enhancing diagnostic accuracy and improving patient outcomes.”
Editorial Opinion: A Beacon of Progress in Cancer Diagnostics
Ibex Medical Analytics stands as a pioneering force in the field of cancer diagnostics. The company’s AI-powered solutions offer substantial advancements in real-world clinical settings, as evidenced by the significant increase in patient cases and new customers. The validation from the Quest Diagnostics study further affirms the effectiveness of Ibex Medical Analytics’ technology in optimizing diagnostic workflows.
The attainment of IVDR certification is particularly noteworthy, given the stringent regulatory environment in Europe. It reflects Ibex Medical Analytics’ unwavering commitment to excellence and adherence to high standards of product quality.
The recent addition of Ann Costello to the board signals a promising future for Ibex Medical Analytics, with her expertise poised to drive the company’s strategic initiatives. As AI continues to integrate into healthcare, Ibex Medical Analytics is well-positioned to lead the charge in enhancing diagnostic precision and patient care.
The company’s trajectory suggests a future where AI and digital pathology converge to significantly improve diagnostic processes. Ibex Medical Analytics’ ongoing innovations highlight its role in shaping the future of cancer diagnostics.
For further information or inquiries, please contact editor@thetimesmag.com.
